Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery.
OBJECTIVE
To evaluate the efficacy of topical lomefloxacin 0.3% versus chloramphenicol 0.2% with polymyxin B 2500 U/ml in the treatment of patients after strabismus surgery.


METHODS
Seventy-nine consecutive patients who underwent strabismus surgery from April through October 2006 were randomized to receive topical lomefloxacin 0.3% (n = 45, 58 eyes) or chloramphenicol 0.2% with polymyxin B 2500 U/ml (n = 34, 40 eyes) postoperatively, in addition to topical dexamethasone 0.1% and diclophenac 0.1%. The groups were compared for clinical signs of local cellulitis and findings on conjunctival cultures.


RESULTS
From postoperative day 1 to day 28, rates of chemosis decreased from 96% to 9.5% in the lomefloxacin group and from 94% to zero in the chloramphenicol group; rates of hyperemia decreased from 100% to zero in both groups. Accordingly, rates of a cumulative clinical sign score (CCSS) decreased from 60% to zero in the lomefloxacin group and 50% to zero in the chloramphenicol group. Rates of positive bacterial cultures dropped from 59.6% preoperatively to 48.3% on day 14 in the lomefloxacin group and from 63% to 47% in the chloramphenicol group.


CONCLUSIONS
Topical lomefloxacin is a potent alternative to topical chloramphenicol eye drops after strabismus surgery for the control of pain, infection and discharge, chemosis, hyperemia, and conjunctival hemorrhage.
Snir
Moshe
M
Pediatric Ophthalmology Unit, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel. msnir@clalit.org.il
Hasanreisoglu
Murat
M
Friling
Ronit
R
Goldenberg-Cohen
Nitza
N
Ehrlich
Rita
R
Bagan
Judith
J
Axer-Siegel
Ruth
R
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006940:Hyperemia / Q000517:prevention & control; D007223:Infant; D008297:Male; D008875:Middle Aged; D009801:Oculomotor Muscles / Q000601:surgery; D010149:Postoperative Pain / Q000517:prevention & control; D011112:Polymyxin B / Q000008:administration & dosage / Q000627:therapeutic use; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D013285:Strabismus / Q000601:surgery*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002701:Chloramphenicol; D011112:Polymyxin B; C053091:lomefloxacin